169 related articles for article (PubMed ID: 36564459)
1. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Yezefski T; Cheng HH; Mostaghel E; Haffner MC; Patel RA; De Sarkar N; Ha G; Dumpit R; Woo B; Lin A; Panlasigui P; McDonald N; Lai M; Nega K; Hammond J; Grivas P; Hsieh A; Montgomery B; Nelson PS; Yu EY
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):194-200. PubMed ID: 36564459
[TBL] [Abstract][Full Text] [Related]
2. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
4. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
[TBL] [Abstract][Full Text] [Related]
5. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
6. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
Denmeade S; Lim SJ; Isaaccson Velho P; Wang H
Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545
[TBL] [Abstract][Full Text] [Related]
7. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
8. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
[TBL] [Abstract][Full Text] [Related]
9. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
Caputo SA; Hawkins M; Jaeger EB; Fleming W; Casado C; Manogue C; Huang M; Lieberman A; Light M; Sussman IP; Miller P; Barata PC; Lewis BE; Layton JL; Ledet EM; Antonarakis ES; Sartor O
Prostate; 2023 Jun; 83(9):879-885. PubMed ID: 36959766
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
13. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Fizazi K; Retz M; Petrylak DP; Goh JC; Perez-Gracia J; Lacombe L; Zschäbitz S; Burotto M; Mahammedi H; Gravis G; Bastos DA; McCune SL; Vázquez Limón JC; Kwan EM; Castellano D; Fléchon A; Saad F; Grimm MO; Shaffer DR; Armstrong AJ; Bhagavatheeswaran P; Amin NP; Ünsal-Kaçmaz K; Wang X; Li J; Loehr A; Pachynski RK
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35977756
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
Markowski MC; Kachhap S; De Marzo AM; Sena LA; Luo J; Denmeade SR; Antonarakis ES
Clin Genitourin Cancer; 2022 Apr; 20(2):97-101. PubMed ID: 34538582
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
18. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
[TBL] [Abstract][Full Text] [Related]
19. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
20. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]